World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   298 records for 39 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3 4
Recruitment statusProspective RegistrationMain ID Public TitleDate of Registration
Not recruitingYesNCT02709408
European Prospective Cohort Study on Enterobacteriaceae Showing Resistance to Carbapenems
02/03/2016
AuthorisedYesEUCTR2015-000515-41-CZ
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2015-000515-41-ESA RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN31/07/2015
AuthorisedEUCTR2015-000515-41-HUA RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN16/07/2015
AuthorisedEUCTR2015-000515-41-PLA RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMEN09/09/2015
AuthorisedEUCTR2015-000515-41-ITA RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM CONTAINING CHEMOTHERAPY REGIMEN.30/09/2016
RecruitingNCT02499120Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer13/07/2015
30/06/2015
Not RecruitingYesCTRI/2015/03/005597
To compare the effect of Tiotropium 5 ug and Olodaterol 5 ug in fixed dose combination over Tiotropium 5 ug in reducing Moderate to severe worsening of a disease in patients with severe to very severe Chronic Obstructive Pulmonary disease
02-03-2015
AuthorisedYesEUCTR2014-002275-28-IT
Comparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2014-002275-28-GRComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.29/01/2015
AuthorisedEUCTR2014-002275-28-SIComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.22/01/2015
AuthorisedEUCTR2014-002275-28-LVComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.05/01/2015
AuthorisedEUCTR2014-002275-28-HUComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.19/11/2014
AuthorisedEUCTR2014-002275-28-ESComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.25/11/2014
AuthorisedEUCTR2014-002275-28-SEComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.10/11/2014
AuthorisedEUCTR2014-002275-28-BEComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.18/11/2014
AuthorisedEUCTR2014-002275-28-GBComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.24/11/2014
AuthorisedEUCTR2014-002275-28-IEComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.28/11/2014
AuthorisedEUCTR2014-002275-28-HRComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.02/04/2015
AuthorisedEUCTR2014-002275-28-CZComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.29/12/2014
AuthorisedEUCTR2014-002275-28-LTComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.29/12/2014
AuthorisedEUCTR2014-002275-28-DKComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.13/11/2014
AuthorisedEUCTR2014-002275-28-PTComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.10/11/2014
AuthorisedEUCTR2014-002275-28-ATComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.27/11/2014
AuthorisedEUCTR2014-002275-28-FIComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.28/10/2014
AuthorisedEUCTR2014-002275-28-SKComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.07/01/2015
AuthorisedEUCTR2014-002275-28-BGComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.05/03/2015
AuthorisedEUCTR2014-002275-28-DEComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.13/01/2015
Not recruitingNCT02296138Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.19/11/2014
AuthorisedEUCTR2014-002275-28-PLComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.09/04/2015
AuthorisedEUCTR2014-002275-28-NLComparing the efficacy of tiotropium + olodaterol (5/5 µg) fixed dose combination (FDC) over tiotropium 5µg in reducing moderate to severe exacerbations in patients with severe to very severe Chronic Obstructive Pulmonary Disease.18/11/2014
28/10/2014
AuthorisedYesEUCTR2013-000490-79-GR
Study to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-000490-79-GBA specially designed study conducted at many medical sites to compare whether Masitinib, in combination with a currently available medicine called Folfiri, to placebo in combination with Folfiri, is safe and effective in second line treatment of patients with advanced colorectal cancer.07/07/2014
AuthorisedEUCTR2013-000490-79-SKStudy to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy29/05/2014
AuthorisedEUCTR2013-000490-79-FRStudy to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy16/06/2015
AuthorisedEUCTR2013-000490-79-HUStudy to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy06/06/2014
AuthorisedEUCTR2013-000490-79-CZStudy to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy28/05/2014
Not RecruitingEUCTR2013-000490-79-ESStudy to evaluate 2 types of treatment (masitinib + FOLFIRI or placebo + FOLFIRI) in the treatment of patients with metastatic colorectal cancer that have received 1 previous therapy22/05/2014
30/01/2014
AuthorisedYesEUCTR2012-005012-26-BE
A CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-005012-26-ESA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES12/11/2013
AuthorisedEUCTR2012-005012-26-ITA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES04/10/2013
AuthorisedEUCTR2012-005012-26-HUA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES11/11/2013
Not AvailableEUCTR2012-005012-26-Outside-EU/EEAA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES18/06/2014
AuthorisedEUCTR2012-005012-26-LVA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES14/04/2014
AuthorisedEUCTR2012-005012-26-CZA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES25/10/2013
AuthorisedEUCTR2012-005012-26-BGA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES19/05/2014
AuthorisedEUCTR2012-005012-26-ROA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES13/05/2014
AuthorisedEUCTR2012-005012-26-EEA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES16/01/2014
AuthorisedEUCTR2012-005012-26-PLA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES22/01/2014
AuthorisedEUCTR2012-005012-26-LTA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES10/06/2014
AuthorisedEUCTR2012-005012-26-GRA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES02/10/2015
AuthorisedEUCTR2012-005012-26-SKA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES07/11/2013
AuthorisedEUCTR2012-005012-26-HRA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES05/11/2014
AuthorisedEUCTR2012-005012-26-SIA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES08/10/2014
AuthorisedEUCTR2012-005012-26-DEA CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS AN ADD ON THERAPY IN CHILDREN WITH EPILEPSY WITH PARTIAL ONSET SEIZURES26/08/2015
RecruitingNCT01964560Long-term Extension Study to Investigate Lacosamide as an Add-on Therapy in Children With Partial Onset Seizures14/10/2013
02/10/2013
Not RecruitingYesEUCTR2010-022134-89-HU
Efficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2010-022134-89-SIEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.15/11/2013
AuthorisedEUCTR2010-022134-89-ESEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.01/10/2013
AuthorisedEUCTR2010-022134-89-ITEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.20/09/2013
Not RecruitingEUCTR2010-022134-89-NLEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.04/10/2013
Not RecruitingEUCTR2010-022134-89-EEEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.14/10/2013
Not RecruitingEUCTR2010-022134-89-LTEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.24/10/2013
Not RecruitingEUCTR2010-022134-89-DKEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.23/01/2014
AuthorisedEUCTR2010-022134-89-HREfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.29/08/2014
AuthorisedEUCTR2010-022134-89-GREfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.17/01/2014
AuthorisedEUCTR2010-022134-89-ATEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.03/02/2014
AuthorisedEUCTR2010-022134-89-PTEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.17/09/2014
AuthorisedEUCTR2010-022134-89-SKEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.14/10/2013
AuthorisedEUCTR2010-022134-89-CZEfficacy and safety of trimetazidine in patients with angina having been treated by dilatation of coronary arteries.17/10/2013
11/09/2013
AuthorisedYesEUCTR2013-000951-42-GB
Roxadustat in the treatment of anemia in chronic kidney disease patients
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-000951-42-ESFG-4592 in the treatment of anemia in chronic kidney disease patients31/10/2013
AuthorisedEUCTR2013-000951-42-SIFG-4592 in the treatment of anemia in chronic kidney disease patients12/11/2013
AuthorisedEUCTR2013-000951-42-FRFG-4592 in the treatment of anemia in chronic kidney disease patients14/05/2014
AuthorisedEUCTR2013-000951-42-HRFG-4592 in the treatment of anemia in chronic kidney disease patients03/09/2014
AuthorisedEUCTR2013-000951-42-LVRoxadustat in the treatment of anemia in chronic kidney disease patients19/02/2014
AuthorisedEUCTR2013-000951-42-DERoxadustat in the treatment of anemia in chronic kidney disease patients04/09/2013
AuthorisedEUCTR2013-000951-42-SERoxadustat in the treatment of anemia in chronic kidney disease patients07/03/2014
AuthorisedEUCTR2013-000951-42-CZRoxadustat in the treatment of anemia in chronic kidney disease patients07/11/2013
AuthorisedEUCTR2013-000951-42-FIRoxadustat in the treatment of anemia in chronic kidney disease patients27/12/2013
AuthorisedEUCTR2013-000951-42-NLRoxadustat in the treatment of anemia in chronic kidney disease patients04/11/2013
AuthorisedEUCTR2013-000951-42-IERoxadustat in the treatment of anemia in chronic kidney disease patients02/12/2013
AuthorisedEUCTR2013-000951-42-DKRoxadustat in the treatment of anemia in chronic kidney disease patients23/12/2013
AuthorisedEUCTR2013-000951-42-ATRoxadustat in the treatment of anemia in chronic kidney disease patients27/11/2013
AuthorisedEUCTR2013-000951-42-PTFG-4592 in the treatment of anemia in chronic kidney disease patients25/11/2013
AuthorisedEUCTR2013-000951-42-HURoxadustat in the treatment of anemia in chronic kidney disease patients14/06/2016
RecruitingNCT02021318Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa20/12/2013
AuthorisedEUCTR2013-000951-42-SKRoxadustat in the treatment of anemia in chronic kidney disease patients11/11/2013
RecruitingDRKS00008827A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis12/08/2015
03/09/2013
Not recruitingYesNCT01921205
Study to Investigate Lacosamide as Add-on Therapy in Subjects =4 Years to <17 Years of Age With Partial Onset Seizures
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-004996-38-ESA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study21/10/2013
AuthorisedEUCTR2012-004996-38-ITA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study02/09/2013
Not AvailableEUCTR2012-004996-38-Outside-EU/EEAA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study18/06/2014
AuthorisedEUCTR2012-004996-38-LVA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study06/09/2013
AuthorisedEUCTR2012-004996-38-ROA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study13/05/2014
AuthorisedEUCTR2012-004996-38-BEA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study02/09/2013
AuthorisedEUCTR2012-004996-38-EEA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study10/09/2013
AuthorisedEUCTR2012-004996-38-CZA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study10/10/2013
AuthorisedEUCTR2012-004996-38-HUA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study27/08/2013
AuthorisedEUCTR2012-004996-38-BGA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study14/03/2014
AuthorisedEUCTR2012-004996-38-LTA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study27/01/2014
AuthorisedEUCTR2012-004996-38-HRA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study04/09/2014
AuthorisedEUCTR2012-004996-38-SKA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study28/08/2013
AuthorisedEUCTR2012-004996-38-SIA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study21/08/2014
AuthorisedEUCTR2012-004996-38-PLA study to test the safety and efficacy of lacosamide in children with epilepsy who are already taking anti-epileptic medications. Children aged 4 years and older but less than 17 year can participate in the study20/12/2013
08/08/2013
Not recruitingYesNCT01830647
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum
10/04/2013
     
1 2 3 4
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history